Diabetes mellitus affects about 20 million Brazilians; System already offers free access to NPH and regular human insulin
It has announced the expansion of access to rapid and prolonged similar action insulins for patients with type 2 diabetes in primary health care. Mellitus, which affects approximately 20 million Brazilians, is a chronic disease that can cause serious heart complications, arteries, eyes, kidneys and nerves.
The initiative expands therapeutic options for patients from (Unified Health System) and contributes to the reduction of the risk of shortage. Currently, the system has already offered free access to NPH and regular human insulins for over 20 years, both in the UBS (Basic Health Units)
The transition to analogous insulins will gradually begin by 2025. The measure will initially prioritize patients over 70 years, according to expert guidelines and studies that highlight the high prevalence of diabetes in this age group.
In, the Ministry of Health also celebrated the approval of the first PDP (Partnership for Productive Development) for the national manufacture of prolonged analogous insulin (glargine). The ministry stated that “This achievement strengthens the economic-industrial complex of health, promoting greater autonomy in the production of essential medicines in Brazil.”
Diabetes
Diabetes mellitus is a disease caused by insufficient production or malabsorption of insulin, a hormone that regulates blood glucose and ensures energy for the body. It can cause increased blood glucose and high rates can lead to complications in the heart, arteries, eyes, kidneys and nerves. In more severe cases, it can lead to death.
With information from.
